11 Dec 2015 07:00
Premaitha Health PLC
Notification of Half Year Results Date
Manchester, UK - 11 December 2015: Premaitha Health PLC (AIM: NIPT, "Premaitha" or the "Company"), developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT), will announce its half year results for the six months ended 30 September 2015 on Monday 14 December 2015.
A group analyst briefing will be held at 9.30am on Monday 14 December 2015 at Instinctif Partners' offices at65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email premaitha@instinctif.com to register.
-Ends-
For more information, please contact:
| |
Premaitha Health PLC Dr Stephen Little, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing
| Tel: +44 (0) 161 667 1053 investors@premaitha.com
|
Cairn Financial Advisers LLP (NOMAD) Liam Murray / Avi Robinson
| Tel: +44 (0) 20 7148 7900 |
Panmure Gordon (UK) Limited (Broker) Robert Naylor (Corporate Finance) Maisie Atkinson (Corporate Broking)
| Tel: +44 (0) 20 7886 2714 Tel: +44 (0) 20 7886 2699 |
Instinctif Partners Melanie Toyne Sewell / Jayne Crook / Emma Barlow | Tel: +44 (0) 207 457 2020 premaitha@instinctif.com |
Notes to Editors
About Premaitha Health
Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is a non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. It has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress.
The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. The Company also has a registered clinical laboratory in Manchester providing an NIPT screening service directly to healthcare professionals and to support their laboratory customers. Premaitha's strategy is to accelerate the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the London Stock Exchange (AIM: NIPT) and is ISO 13485:2003 certified. Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK.
For further information please visit www.premaitha.com or email iona@premaitha.com